• LAST PRICE
    7.2000
  • TODAY'S CHANGE (%)
    Trending Up0.0700 (0.9818%)
  • Bid / Lots
    7.1900/ 9
  • Ask / Lots
    7.2000/ 6
  • Open / Previous Close
    7.1800 / 7.1300
  • Day Range
    Low 6.9900
    High 7.2600
  • 52 Week Range
    Low 4.0040
    High 40.6000
  • Volume
    201,459
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 7.13
TimeVolumeOTLK
09:32 ET32047.17
09:36 ET76727.1101
09:38 ET40227.1
09:39 ET11007.0984
09:41 ET20007.0302
09:43 ET24917.07
09:45 ET39747.13
09:48 ET3497.15
09:50 ET42407.0801
09:52 ET82757
09:54 ET52717
09:56 ET21997
09:57 ET116527
09:59 ET106527.16
10:01 ET40307.17
10:03 ET30757.11
10:06 ET3007.14
10:08 ET9907.115
10:10 ET2007.1099
10:12 ET6007.085
10:14 ET1007.065
10:17 ET11807.08
10:24 ET7007.0293
10:26 ET6217.04
10:28 ET1007.03
10:32 ET38397
10:33 ET2007.01
10:35 ET12007.02
10:37 ET1007.02
10:39 ET2007.02
10:42 ET75327.0001
10:44 ET9997.0003
10:46 ET70407.02
10:48 ET3007.05
10:50 ET6007.08
10:51 ET16387.0726
10:53 ET1137.08
10:55 ET1007.08
10:57 ET1007.08
11:00 ET1007.085
11:04 ET31727.12
11:06 ET3007.15
11:08 ET29267.16
11:09 ET4197.1701
11:15 ET1007.13
11:20 ET1007.11
11:22 ET4397.115
11:24 ET1007.115
11:27 ET3007.115
11:31 ET8607.09
11:33 ET26927.1
11:38 ET3007.12
11:42 ET6007.11
11:44 ET7417.06
11:47 ET11287.03
11:49 ET1257.0406
11:51 ET4007.03
11:56 ET4007.0649
11:58 ET2007.05
12:00 ET5207.055
12:02 ET2007.065
12:07 ET1007.09
12:09 ET2007.07
12:16 ET4007.07
12:18 ET9007.06
12:20 ET1007.04
12:23 ET7827.0354
12:30 ET2837.0475
12:32 ET6447.0101
12:34 ET12007.06
12:36 ET7007.07
12:38 ET4007.1
12:39 ET1007.1
12:41 ET5007.1
12:45 ET6647.185
12:48 ET3007.17
12:50 ET5007.17
12:52 ET1007.145
12:54 ET11847.1876
12:56 ET1007.215
12:57 ET1127.1907
01:03 ET7507.19
01:12 ET6177.167
01:15 ET11597.19
01:17 ET2507.205
01:19 ET1007.2
01:21 ET5007.18
01:44 ET3007.18
01:46 ET35987.165
01:48 ET2007.155
01:55 ET6157.14
02:00 ET15007.1591
02:13 ET6007.12
02:18 ET11007.115
02:22 ET10007.1
02:24 ET2007.115
02:27 ET26007.08
02:31 ET32397.05
02:36 ET3337.0325
02:42 ET2007.0285
02:44 ET2007.02
02:45 ET5037.03
02:47 ET1317.0201
02:49 ET52467.09
02:51 ET1007.11
02:54 ET7737.145
02:56 ET10487.145
02:58 ET4007.145
03:03 ET14727.16
03:05 ET2007.16
03:09 ET8637.14
03:12 ET1007.125
03:16 ET4007.11
03:25 ET1007.095
03:27 ET16587.11
03:30 ET3007.105
03:32 ET6017.11
03:34 ET19467.14
03:38 ET23637.18
03:39 ET2007.22
03:41 ET10007.2
03:43 ET4837.1912
03:45 ET8887.195
03:48 ET2007.2
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesOTLK
Outlook Therapeutics Inc
166.9M
-0.6x
---
United StatesATOS
Atossa Therapeutics Inc
166.0M
-5.6x
---
United StatesRZLT
Rezolute Inc
165.8M
-3.7x
---
United StatesGLSI
Greenwich Lifesciences Inc
169.6M
-18.6x
---
United StatesGALT
Galectin Therapeutics Inc
173.4M
-3.7x
---
United StatesXFOR
X4 Pharmaceuticals Inc
156.9M
-1.4x
---
As of 2024-05-30

Company Information

Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.

Contact Information

Headquarters
111 S. Wood Avenue, Unit #100ISELIN, NJ, United States 08830
Phone
609-619-3990
Fax
---

Executives

Independent Executive Chairman of the Board
Ralph Thurman
President, Chief Executive Officer, Director
C. Russell Trenary
Chief Financial Officer, Executive Vice President, Treasurer, Company Secretary, Director
Lawrence Kenyon
Senior Vice President - Head of Europe
Jedd Comiskey
Senior Vice President - Licensing and M&A
Joel Prieve

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$166.9M
Revenue (TTM)
$0.00
Shares Outstanding
23.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.65
EPS
$-11.48
Book Value
$-1.11
P/E Ratio
-0.6x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.